Merck & Co. stock jumps to record high as cancer vaccine data eases Keytruda risk

Merck & Co., Inc. (US58933Y1055) stock has rallied sharply in August 2026, with shares closing at $152.32 on the New York Stock Exchange on August 19, 2026, up 12.69% on the day and valuing the company at about $375.50 billion. Market data show the move pushed the stock to a record region after breaking successive resistance levels on the chart.

Phase 3 cancer vaccine win supports oncology pipeline

Fresh momentum for Merck & Co. is tied to new late-stage data for a cancer vaccine that bolsters the company’s oncology pipeline and helps address investor concerns about long-term dependence on Keytruda. One report on August 20, 2026, notes that Merck added to its oncology assets following a successful phase 3 result, which helped drive a double-digit percentage gain in the stock and a move to a new record high.

According to the same analysis, Merck shares climbed after traders interpreted the vaccine data as easing long-term Keytruda risk by broadening the company’s cancer-treatment portfolio. The report highlights that Merck stock rose 12% on the day of the announcement and briefly touched a fresh record, underscoring how sensitive the valuation remains to developments in the oncology franchise. At an intraday level, the stock was trading close to technical resistance around $153.07 to $153.13, with potential upside targets flagged at $158.61 and $162.03 if momentum continues.

Q2 2026 results show 5% sales growth and concentration in oncology

While the latest vaccine news supplied the catalyst, the fundamental backdrop comes from Merck’s second-quarter 2026 results. The same report states that Merck generated second-quarter 2026 sales of $16.61 billion, a 5% increase versus the same quarter a year earlier and above the $16.36 billion analyst consensus referenced in the piece. That 5% growth rate, combined with a modest beat versus expectations of roughly $250 million, suggests the core portfolio is still expanding despite ongoing price and patent pressures in parts of the business.

Oncology remains the centerpiece. The report indicates that combined sales of Keytruda and its subcutaneous formulation, described as QLEX, reached $8.37 billion in the second quarter of 2026, up 5% over the prior-year period and representing more than half of Merck’s revenue from operations. Within that total, QLEX contributed $463 million in the quarter, illustrating the rapid uptake of the new formulation and its potential to extend the franchise. For investors, the number stands out: Keytruda-related products alone accounted for over 50% of company revenue in the quarter, reinforcing both Merck’s competitive strength in immuno-oncology and its exposure to a single class of therapies.

Beyond oncology, Merck showed healthy growth in several other franchises. The same Q2 snapshot notes that WINREVAIR generated $588 million in sales, up 75% from the year-earlier period, driven by higher pulmonary hypertension product demand. The Animal Health division delivered $1.78 billion in revenue, an increase of 8% year over year, signaling resilience in companion-animal and livestock markets. Vaccines also remained a key pillar: Gardasil sales reached $1.17 billion in the quarter, while the pneumococcal vaccine Capvaxxive contributed $184 million. Together, these figures indicate that Merck’s growth is diversified across cardiometabolic, animal health, and vaccine lines even as oncology leads the overall profile.

Despite solid top-line performance, earnings were pressured by deal-related costs. The report highlights that Merck recorded a GAAP loss of $0.54 per share in the second quarter of 2026 and a non-GAAP loss of $0.13 per share, with both figures driven primarily by a $5.7 billion acquisition-related charge, or $2.31 per share, linked to the purchase of Terns Pharmaceuticals and its chronic myeloid leukemia candidate MK-4208. This one-time hit is central to understanding why the company reported a loss in a quarter that otherwise delivered revenue growth and strength in key products.

The same analysis points to Merck’s updated profitability outlook. Management now expects adjusted operating EPS in a range of $2.66 to $2.76 for the current year, incorporating positive contributions from recent transactions and development programs as well as the sizable charges from the Terns deal and another acquisition. The report mentions a $3.62 per share contribution tied to a Cidara Therapeutics transaction and reiterates the $2.31 per share impact from the Terns acquisition, emphasizing that investors should separate recurring earnings power from these discrete items when evaluating valuation.

Stock valuation stretched versus intrinsic estimates

The strength in Merck stock has raised questions about valuation. A separate fundamental screen published on August 19, 2026, observed that Merck shares closed at $152.20, matching the $152.32 closing level seen in other market data sources and implying a sizable premium to estimated intrinsic value. One valuation model cited in that report assigns Merck a fair value estimate of $119.87, indicating the stock is 27.0% overvalued at a price of $152.20.

An earlier snapshot from the same data provider, taken when Merck traded at $135.17, indicated that the stock was 12.8% overvalued versus the same $119.87 fair value estimate. That commentary framed the premium as manageable but urged caution regarding long-run dividend sustainability. Now, with the share price having advanced by 12.6% to the $152 range, the implied overvaluation has expanded from 12.8% to 27.0%. For income-oriented investors, that combination of a higher valuation multiple and deal-driven EPS volatility may temporarily constrain upward revisions to dividend-growth expectations.

Other real-time quote sources echo the strong recent move. One consolidated quote page shows Merck stock trading at $151.50 on August 20, 2026, with the shares having touched an intraday high of $154.50 and a low of $141.80 during the session. That overview also cites a market capitalization of $375.58 billion and notes that, at $151.50, the stock was 6.8% above the session low and 1.9% below the high. In practical terms, those numbers show Merck consolidating just under its latest peak after a sharp one-day jump.

At the same time, another real-time feed on August 20, 2026, shows Merck at $149.82 shortly before 10:00 a.m. Eastern Time, up 10.84% on the session with a previous close of $135.17 and an open of $146.94. That snapshot confirms that the largest part of the move occurred on August 19 and carried into the next trading session, leaving Merck trading more than $14 above its prior close and setting a fresh 52-week and annual high at $153.50 according to a separate market recap.

Analyst sentiment and consensus context

Against this backdrop, several market commentators have pointed to both the earnings beat and the oncology pipeline news as drivers of analyst optimism. A same-day news summary notes that Merck stock surged to a 52-week high of $153.50, posting its biggest one-day percentage gain since March 2009, and closed at $152.20. The article highlights that the move took Merck more than 12.6% higher, aligning with the percentage change shown in multiple quote feeds.

Another live commentary stream on August 19, 2026, emphasized that Merck shares were trending higher early in the day and later extended those gains as investors digested the Q2 numbers and vaccine update. The feed described the stock as a trending name in the healthcare sector, with traders closely watching the elevated volume and the break above prior resistance levels.

While specific target changes were not detailed in the available summaries, the combination of a revenue beat, strength in oncology and vaccines, and high-profile trial success is consistent with a constructive sell-side stance. At the same time, valuation models flag that the stock’s premium to intrinsic value estimates has widened, which could limit further multiple expansion unless new data or guidance revisions support higher long-term earnings power.

Technical backdrop and trading levels

From a technical perspective, the recent move has changed the character of Merck’s chart. The intraday analysis published on August 20, 2026, shows the stock trading at $152.23 on a four-hour chart, having broken through prior resistance levels at $140.64, $144.11, $146.55, and $149.65. The technical review identifies the immediate resistance zone as $153.07 to $153.13, with a potential extension toward $158.61 and then $162.03 if buyers remain in control.

For investors using price levels as a guide, the comparison between the August 19 close of $152.20 and the identified resistance at roughly $153.10 suggests that the stock is trading within 1% of short-term overhead supply. A sustained move above that band could reset the trading range and open a new leg higher, whereas a failure to hold above the $149.65 breakout level might signal consolidation or a partial retracement after the strong move. The fact that intraday lows on August 20 remained above $141.80, well above the $135.17 prior close, indicates that dip buyers have been active even after the news-driven spike.

Keytruda, vaccines, and broader portfolio

Keytruda remains the flagship product in Merck’s oncology franchise. The Q2 2026 revenue figure of $8.37 billion for Keytruda and its subcutaneous partner product illustrates both volume strength and pricing power in immuno-oncology. With that combined total representing more than half of company revenue, Keytruda continues to underpin Merck’s cash generation and research budget. The QLEX formulation, contributing $463 million, underscores how formulation innovation can extend a mature brand’s lifecycle and improve patient convenience.

WINREVAIR’s 75% year-over-year growth to $588 million in Q2 highlights a second growth vector in pulmonary hypertension and related indications. This performance suggests that Merck is successfully commercializing newer medicines outside its core cancer portfolio. The Animal Health unit’s 8% revenue increase to $1.78 billion similarly shows that Merck’s exposure to pet and livestock trends remains a stable contributor, offering some diversification from human pharmaceuticals.

On the vaccine side, Gardasil’s $1.17 billion in quarterly sales reaffirms the strength of Merck’s human papillomavirus franchise, supported by continued uptake in both developed and emerging markets. Capvaxxive’s $184 million in revenue in the same quarter shows that newer vaccines are gaining traction, which can help smooth revenue as older products face competition. These portfolio details matter for equity holders, because they indicate that Merck’s 5% overall sales growth in Q2 2026 is underpinned by multiple franchises rather than a single product.

Representative product: Keytruda in immuno-oncology

Within Merck’s line-up, Keytruda stands as the most representative flagship product for the company’s current investment story. This programmed death receptor-1 (PD-1) blocking antibody is approved in a wide range of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, and several others. The Q2 2026 data showing $8.37 billion in combined sales for Keytruda and its subcutaneous companion product underline how central this therapy is to Merck’s financial results and research strategy.

The company continues to invest heavily in expanding Keytruda’s indications and in combination regimens that pair the medicine with other targeted treatments. The introduction of the subcutaneous formulation, which generated $463 million in the second quarter alone, illustrates a strategic push to improve patient experience and administration flexibility while maintaining the underlying mechanism of action. For patients and clinicians, the variety of indications and dosing formats positions Keytruda as a backbone therapy in many oncology regimens, while for investors it reinforces the importance of monitoring patent timelines, biosimilar competition, and the development of next-generation immunotherapies that could either complement or compete with Merck’s franchise.

Merck & Co. stock price context

Merck & Co. stock trades on the New York Stock Exchange under the ticker MRK, with the latest completed U.S. regular session showing a closing price of $152.32 on August 19, 2026, in U.S. dollars. The quote snapshot for that session lists a market capitalization of $375.50 billion at the close, reflecting the impact of both the phase 3 cancer vaccine result and the second-quarter earnings beat on investor sentiment.

Fact box

Company: Merck & Co., Inc.
ISIN: US58933Y1055
Ticker: MRK
Exchange: NYSE
Price (as of August 19, 2026, 4:00 p.m. ET): $152.32 USD
Market cap: $375.50 billion (as of August 19, 2026)
Sector / Industry: Health care / Pharmaceuticals
Index membership: S&P 500